Novel Tools for Diagnosis and Monitoring of AML
Current Oncology · 23.05.2023 · 30 (6) · 5201-5213
DOI: 10.3390/curroncol30060395 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 23.05.2023. Verfasst von Francesca Guijarro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematopathology Section, Pathology Department, Hospital Clinic Barcelona, 08036 Barcelona, Spain. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (ISCIII).
Abstract (Originalsprache)
In recent years, major advances in the understanding of acute myeloid leukemia (AML) pathogenesis, together with technological progress, have led us into a new era in the diagnosis and follow-up of patients with AML. A combination of immunophenotyping, cytogenetic and molecular studies are required for AML diagnosis, including the use of next-generation sequencing (NGS) gene panels to screen all genetic alterations with diagnostic, prognostic and/or therapeutic value. Regarding AML monitoring, multiparametric flow cytometry and quantitative PCR/RT-PCR are currently the most implemented methodologies for measurable residual disease (MRD) evaluation. Given the limitations of these techniques, there is an urgent need to incorporate new tools for MRD monitoring, such as NGS and digital PCR. This review aims to provide an overview of the different technologies used for AML diagnosis and MRD monitoring and to highlight the limitations and challenges of current versus emerging tools.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematopathology Section, Pathology Department, Hospital Clinic Barcelona, 08036 Barcelona, Spain.
- Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
- Hematology Department, Hospital Clinic Barcelona, 08036 Barcelona, Spain.
ORCID-Profile: Francesca Guijarro, Marta Garrote, Dolors Colomer, Mónica López-Guerra
Förderung
- Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (ISCIII)
Zitieren
APA
Guijarro, F., Garrote, M., Villamor, N., Colomer, D., Esteve, J., & López-Guerra, M. (2023). Novel Tools for Diagnosis and Monitoring of AML. Current Oncology, 30(6), 5201-5213. https://doi.org/10.3390/curroncol30060395
Vancouver
Guijarro F, Garrote M, Villamor N, Colomer D, Esteve J, López-Guerra M. Novel Tools for Diagnosis and Monitoring of AML. Current Oncology. 2023;30(6):5201-5213. doi:10.3390/curroncol30060395
BibTeX
@article{Guijarro2023,
author = {Guijarro, Francesca and Garrote, Marta and Villamor, Neus and Colomer, Dolors and Esteve, Jordi and López-Guerra, Mónica},
title = {Novel Tools for Diagnosis and Monitoring of AML},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {6},
pages = {5201--5213},
doi = {10.3390/curroncol30060395}
}
EUVIMED